This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

OPEN ACCESS - PLEASE RSVP TO RESERVE YOUR SEAT


Cell & Gene Therapies State of the Industry Briefing
Cell & Gene Therapies State of the Industry Briefing

Monday, January 13, 8:00-10:45 am 
Parc 55 San Francisco, Cyril Magnin Ballroom

Join us for the Alliance for Regenerative Medicine’s 10th Annual Cell & Gene Therapies State of the Industry Briefing, a top-level gathering for key stakeholders in the field. This event – which is free and open to the public – will include ARM’s annual yearly update on the sector’s progress, as well as two panels featuring top CEOs and executives highlighting future inflection points for cell and gene therapies in 2020. With an anticipated audience of over 500, this session is the largest cell and gene therapy-focused event taking place during JP Morgan week.

RSVP here
The impact of AI: How AI and ML are transforming R&D, and what's next to come
The impact of AI: How AI and ML are transforming R&D, and what's next to come

Monday, January 13, 4:00-5:00 pm 
Parc 55 San Francisco, Cyril Magnin Ballroom

Artificial Intelligence is significantly influencing global healthcare including drug development. This discussion will highlight how AI, and specifically, machine learning, is being used to: identify novel therapeutics; find, characterize and intervene on behalf of patients; integrate Social Determinants of Health (SDOH) and other data to provide new insights into patient care; and ultimately enable companies to work more efficiently and effectively. The panel will also explore trends and implications in partnering, business models and capital formation that impact the innovation and adoption of AI in healthcare. 

Speakers include:

  • Moderator: Hannah Kuchler – US Pharma and Biotech Correspondent, Financial Times
  • Ron Alfa – Senior VP, Translational Discovery and Chief Evangelist, Recursion Pharmaceuticals
  • Anastasia Christianson – VP, R&D Operations and Oncology IT, Janssen Pharmaceutical Companies of Johnson & Johnson
  • Zavain Dar – Partner, Lux Capital
  • Rafael Rosengarten – CEO and Co-Founder, Genialis, Inc.
  • Oodaye Shukla – Chief Data and Analytics Officer, HVH Precision Analytics
RSVP here
Demystifying the Value of AI for Rare Disease Science and Treatment
Demystifying the Value of AI for Rare Disease Science and Treatment

Tuesday, January 14, 4:30-5:15 pm
Hilton San Francisco Union Square, Imperial Ballroom

Artificial intelligence is being heralded as the next revolution. For rare disease, that revolution is already beginning: artificial intelligence is accelerating patient diagnosis, target discovery, drug discovery, and clinical care through efforts by academic researchers, industry, and patient advocacy groups.

Moderator: John Reynders, VP, Data Sciences, Genomics, and Bioinformatics, Alexion Pharmaceuticals

  • Ranjeet Alexis – Investment Director Intel Capital
  • Carrie Burke – VP, Business Development and Partnerships, Clinithink
  • Dave Bjork – Director of Community Relations, FRAXA Research Foundation
  • Tim Guilliams – CEO & Co-Founder, Healx
  • Charlotte Hobbs – VP Research & Clinical Management, Rady Children’s Institute for Genomic Medicine
RSVP here

Running global trials with regional CRO partners
Running global trials with regional CRO partners

Tuesday, January 14, 5:30 pm
Parc 55 San Francisco, Level 3, Embarcadero

Novotech, the Asia Pacific CRO, will be hosting a free research briefing on how Asia’s vast patient pools, high-quality infrastructure, lower trial concentration, comparable quality and lower costs make it a key destination for biotechnology companies for later phase trials. As the region with the fastest-growing clinical activity, Asia is becoming increasingly attractive to European and North American biotechs. This progress in clinical trial activity is the result of a series of changes in the Asia-Pacific region in recent months. Join us for this free briefing where we will be providing complimentary drinks and refreshments.

RSVP here
Media Roundup: Heard around the Square
Media Roundup: Heard around the Square

Wednesday, January 15, 4:30-5:15 pm 
Hilton San Francisco Union Square, Imperial Ballroom

As the most important week of the biotech calendar draws to a close, join us to hear what trends and issues will reverberate as we start a new decade. This media panel will provide their take on what was heard around Union Square and break down the most important news stories you should take away from the week. Who were the newsmakers in 2019 and who to watch in 2020? What does the industry need to prepare for next year and beyond?

Moderator: Jeff Cranmer, Executive Editor, BioCentury Inc.

  • Riley Griffin – U.S. Health Care & Pharmaceuticals Reporter, Bloomberg News
  • Matthew Herper – Senior Writer, Medicine, and Editorial Director, Events, STAT
RSVP here

Additional Events


China Showcase
China Showcase

Sunday, January 12, 7:00 am - 5:30 pm
Parc 55 San Francisco

TAP INTO CROSS-BORDER INVESTMENT AND COLLABORATION OPPORTUNITIES AT CHINA SHOWCASE!
Meet and network with top bio pharmaceutical companies and investors seeking global opportunities during Biotech Showcase.

Register now
Digital Medicine & Medtech Showcase
Digital Medicine & Medtech Showcase

Monday -  Wednesday, January 13-15
Parc 55 San Francisco


INNOVATE. CONNECT. FUND.
At the intersection of technology and medicine: Digital Medicine & Medtech Showcase

Register now